Sasha Blaug

Updated results from Celgene's (NASDAQ: CELG) MM-015 study reaffirmed Revlimid's efficacy in improving progression free survival (PFS). The analysts said, "We believe that the data will support US and EU filing in front line MM. While US approval will likely have limited impact, as Revlimid is...

M. Ian Somaiya and Sasha Blaug, analysts at Piper Jaffray, have given a ‘Neutral’ rating to Amgen (NASDAQ: AMGN), which develops treatments for anemia, cancer, & other diseases. The target price is at $61.00 and the stock has been trading at $54.34. Phase III studies of Denosumab have...

Piper Jaffray analysts M. Ian Somaiya and Sasha Blaug maintained their Neutral rating for shares of BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), while raising the price target to $25 from the previous price target of $23. The analysts noted that BioMarin Pharmaceutical Inc released financial...